Amgen: Strong growth company with a challenging future
- Pages: 27
- Published: December 2015
- Report Code: ML00019-063
Since it was founded in 1980, Amgen has established itself as a leading global biotechnology company and built increasingly strong human therapeutics brands as well as state of the art manufacturing facilities. This case study analyses the company's recent financial performance, evaluates the strategies that have helped it become a global leader, and explores what the future may hold.
Investigation of Amgen’s success and a detailed analysis of its rise to be one of the most innovative biotechnology companies in the world.
Parallel comparisons in terms of R&D, stock market and financial performance to identify its strengths and weaknesses among its peers.
Analysis of the challenges that Amgen faces both internally and externally.
The case study also focuses on the R&D and acquisition strategy of the company.
Reasons to buyHow did Amgen become the world's leading Biotechnology company?
What are the key challenges the company now faces?
Table of Contents
CONSISTENT GROWTH ACCOMPANIED WITH SIGNIFICANT CHALLENGES
AMGen to Amgen
Rapid growing, profitable multi-billion dollar business
Reliance on Neulasta and ENBREL
Dependence on North America
Strong stock market performance
FOCUSED AND WELL-MANAGED R&D
Amgen: An innovative human therapeutics company
Organic growth stimulated by committed R&D investment
Acquisitions continues to reap great results
BOTH INTERNAL AND EXTERNAL CHALLENGES AHEAHD
Challenges within the organization
Inability to produce blockbuster drugs
Litigation settlements hurt Amgen’s financial performance
Difficult external challenges ahead
The rise of Gilead
Opportunity coincides with challenge for Amgen
Ask the analyst
List of Tables
List of Figures